Altamira Therapeutics Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas Meyer
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Bahnhofstrasse 21 Zug ZUG Switzerland HM 11
- IPO Date
- Aug 6, 2014
- CIK
- 0001601936
- Website
- aurismedical.com
- Similar Companies
- Business
- Altamira Therapeutics Ltd. Altamira Therapeutics Ltd. (CYTOF) is a Bermuda-based biopharmaceutical company that develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues via its proprietary xPhore platform, including OligoPhore, SemaPhore, CycloPhore, and GenePhore components; the platform supports siRNA, mRNA, circular RNA, and DNA payloads for applications in oncology, immunology, and vaccines, with flagship preclinical programs AM-401 targeting KRAS-driven cancers through tumor-specific siRNA gene knockdown and AM-411 addressing rheumatoid arthritis via NF-kB pathway inhibition in inflamed tissues. The company, founded in 2003 as Auris Medical and headquartered in Hamilton, Bermuda with primary operations in Basel, Switzerland, also manages legacy assets in allergology such as the Bentrio drug-free nasal spray for protection against airborne viruses and allergens, and inner ear therapeutics including AM-125 for vertigo, AM-111 for acute hearing loss, and AM-102 for tinnitus, which it is actively divesting or out-licensing. Recent developments include multiple strategic collaborations initiated in 2024 and 2025, such as partnerships with Univercells Group for SemaPhore mRNA vaccine delivery, an undisclosed radiopharmaceutical firm for nanoparticle-enhanced cancer targeting, and another partner evaluating CycloPhore for circular RNA; the company anticipates additional agreements in 2025 and is pursuing private equity investment to spin off its Swiss subsidiary Altamira Therapeutics AG while advancing xPhore toward IND filing and manufacturing scale-up.
Auris Medical Announces Launch of New Corporate Website
5 Reddit Penny Stocks to Watch That Are Moving Right Now
Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19
Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
EARS Stock Price Increases Over 14% Pre-Market
Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs
EARS Stock Price: Over 9% Increase Pre-Market Explanation
Auris Medical Holding to Present at LD Micro Invitational XI Conference
Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo
4 Meme Penny Stocks To Watch As DogeCoin Rises
Auris Medical Stock Is Trading Higher As Bentrio Hit Primary Endpoint Goal In Allergic Rhinitis Study
EARS Stock: Over 30% Increase Intraday Explanation
Auris Medical Provides Update on Bentrio Program in Allergy
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
EARS Stock: Over 9% Increase Pre-Market Explanation
Why Auris Medical, CytoDyn and Prometheus Shares Are Moving Today
EARS Stock Price Increased Over 4% Pre-Market: Why It Happened
Auris Medical Provides Business Update and Reports Second Half and Full Year 2020 Financial Results
EARS Stock Price Increased 52.05%: Why It Happened